Topic:

Partnering

Latest Headlines

Latest Headlines

Pfizer, 23andMe unite to decode bowel disease

Pfizer is reaching out to the Google-backed genomics outfit 23andMe to better understand the root causes of inflammatory bowel disease, looking to mine patient data for clues that could bolster its growing pipeline.

Oraya receives NIH grant to study use of its novel eye radiation tech against cancer

Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.

Medtronic hires former senators to lobby against anti-inversion bill and protect acquisition of Covidien

Medtronic quietly hired former Sens. John Breaux (D-LA) and Trent Lott (R-MS) and three others as lobbyists to combat anti-inversion legislation as political anger over the tax saving method mounts, threatening the planned company's planned merger with Covidien. 

Sanofi fills some big shoes in $925M Afrezza pact with MannKind

MannKind has finally nailed down the major league pharma player it always wanted to roll out its inhaled insulin product Afrezza. But after going it alone to nail down an FDA approval on a new therapy that continues to generate heavy skepticism about its marketing potential, the numbers involved so far are still strictly minor league.

Sanofi taps Immune Design to help battle food allergies

Sanofi has reached out to Seattle biotech Immune Design, looking to borrow the company's drug discovery platform to develop new treatments for food allergies.

Astellas leans on U.K. luminaries for cancer R&D

Japanese drugmaker Astellas Pharma has teamed up with Cancer Research U.K. to join forces on early-stage oncology R&D, working to identify new treatments for pancreatic cancer.

GlaxoSmithKline backs off from Galapagos' anti-inflammatory hopeful

GlaxoSmithKline has again scaled back its expectations for an anti-inflammatory treatment licensed from Galapagos, calling off any plans for late-stage study after a few Phase II miscues dulled the drug's potential.

Quintiles and Roche take to China with testing partnership

Quintiles has signed a deal with a Roche diagnostics subsidiary to offer cancer screenings in China, looking to capitalize on the growing market for clinical trials in the country.

Roche, Quintiles partner for companion diagnostics in China

Ventana and Quintiles are partnering up to provide companion diagnostic testing services in China for early clinical trials. China is among a few countries that requires patient samples used in clinical trials to be tested domestically for inclusion in the country's approval process.

Daiichi Sankyo bets up to $650M on Charleston's pain potential

Daiichi Sankyo, Japan's second-largest pharma outfit, has agreed to pay up to $650 million to get its hands on some hydrocodone combo medications, striking a deal with Charleston Laboratories with hopes of cashing in on the demand for pain pills.